Literature DB >> 2213947

Alternative delivery system for controlled drugs in the surgical intensive care unit.

J A Weigelt1, C Dyke, R L Martin.   

Abstract

Faced with a serious shortage of qualified nurses for critically ill patients, methods to reduce the time required to deliver care without sacrificing quality are needed. A non-electronic device designed as a patient-controlled analgesic (PCA) was evaluated as a nurse-controlled device (NCA). Twenty-five intubated patients received morphine sulfate (MS) with the nurse-controlled device (NCA) and 12 by standard IV push policy. The average nursing time for narcotic dosing with the standard policy was 5 minutes/unit dose. A total of 1,183 NCA doses were given over 77 patient days. The average doses per patient day were 15 (2-38). The average nursing time was 22 seconds/NCA dose. The NCA saved 85 nursing minutes/patient day. Annual nursing labor costs were reduced by $77,000.00 with NCA. Total costs for standard IV push narcotic use were $36.43/patient day versus $35.45/patient day for NCA. Using this protocol, the NCA system saved $8,500.00 annually. By increasing the duration of PCA use to 72 hours, the annual savings would become $49,500.00. These data indicate that a simple NCA can deliver controlled drugs rapidly and safely, save valuable nursing time, and decrease the cost of ICU care.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2213947     DOI: 10.1097/00005373-199009000-00010

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  2 in total

Review 1.  Cost considerations in patient-controlled analgesia.

Authors:  A Jacox; D B Carr; D M Mahrenholz; B M Ferrell
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

2.  Efficacy and safety of a subacromial continuous ropivacaine infusion for post-operative pain management following arthroscopic rotator cuff surgery: a protocol for a randomised double-blind placebo-controlled trial.

Authors:  Jennifer A Coghlan; Andrew Forbes; Simon N Bell; Rachelle Buchbinder
Journal:  BMC Musculoskelet Disord       Date:  2008-04-22       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.